TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of Subjects Experiencing Acute Cellular Rejection
Endpoint domain: Adverse events/effects
Primary endpoint: Current smoking (last 30 days)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Responder rate assessed by ODI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Diet Quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of days on broad-spectrum antibiotics
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Presence of bacteria in normal paranasal sinuses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Objective response rates (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCt of CKD-330, D085, CKD-333
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of CKD-330, D085, CKD-333
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Fat Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participants' Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Evaluation of the Therapy's Safety
Endpoint domain: Adverse events/effects
Primary endpoint: Performance score on driving ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: M30 value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Frequency of Heavy Drinking Days
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adverse Event Frequency
Endpoint domain: Adverse events/effects
Primary endpoint: Alkaline Phosphatase Levels Pre and Post Transplant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Visuomotor Skill
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain Excitability (MEP Amplitude)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Salivary Amylase Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: NPRS - LBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NPRS - Leg pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with treatment failure
Endpoint domain: Adverse events/effects
Primary endpoint: number of gestational diabetes cases diagnosed with OGTT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: difference in HOMA values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in Internalized Stigma
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Area Under the Plasma Concentration - Time Curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent Terminal elimination Half-life (t 1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lumbar Puncture Success - Composite Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in objectively measured cognitive performance (sustained attention)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in objectively measured cognitive performance (inhibitory control)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in objectively measured cognitive performance (working memory)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change from baseline in Alzheimer's Disease Assessment Scale - Cognitive Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from baseline in Mnemonic Similarity Task score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from baseline in Executive Function Composite score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction in visits to health care providers for treatment of illness
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Reduction in drug use; antibiotics and other drugs during diarrheal illnesses
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Increase in ORS use during diarrhea in the intervention communities
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in Ankle Dorsiflexion Range of Motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency and severity of TRM
Endpoint domain: Adverse events/effects
Primary endpoint: Proxy-rated Health Related Quality of Life of the patient
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Informal caregivers burden
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: Cost utility analysis
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in skin microbiome diversity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in transepidermal water loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in stratum corneum hydration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in colorimeter test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in Concussive symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Work Related Issues
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Development of tuberculosis
Endpoint domain: Adverse events/effects
Primary endpoint: Peak plasma concentration (Cmax) of PUR0200
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to reach peak plasma (Tmax) concentration of PUR0200
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration versus time (AUC) of PUR0200
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sitting diastolic blood pressure (DBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pulpal blood flow changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Ambulatory Blood Pressure Reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: clinical size of lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of participants with Dose-limiting toxicity (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percent absolute enhancement of HCCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drop-out Rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Completed Days of Exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extent of late gadolinium enhancement (LGE+%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Spino-sacral angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in allergic rhinitis symptom severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimum FEV1 Between 4-10 Hours After Allergen Challenge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Platelet dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Glycemic control measured by hemoglobin A1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in nasal NO
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in nasal FeNO
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: successful sexual intercourse
Endpoint domain: Life impact
Endpoint subdomain: Sexual functioning
Primary endpoint: improvement in Female sexual functioning index
Endpoint domain: Life impact
Endpoint subdomain: Sexual functioning
Primary endpoint: Wound architecture score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic parameters (Cmax, Cmin, tmax, AUC(0-t), AUC(0-inf), t1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in nerve function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in overall mortality
Endpoint domain: Mortality/survival
Primary endpoint: Bacterial prevalence in acute uncomplicated cystitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Elimination half-life (t1/2) of 10-1074-LS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clearance (CL) of 10-1074-LS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of antimicrobial medications
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Sweat gland function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with self-reported medically-diagnosed chronic diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total number of FOXP3-positive T regulatory cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Healing of the sternum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Ability to Retain Participants
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Clinical response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of participants in syphilis testing
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Time to Clinically Definite Multiple Sclerosis (CDMS) Conversion
Endpoint domain: Mortality/survival
Primary endpoint: Plasma CAB maximum observed concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma CAB area under the concentration versus time (AUC(0-∞))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: blood withdrawal-induced changes in ΔIVCST
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in tumor size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Velocity of disease symptom relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of disease symptom relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Braking performance 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Braking performance 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participant attendance rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Acute Physiology and Chronic Health Evaluation (APACHE) IV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Simplified Acute Physiology Score (SAPS III)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: One-Year Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Erythrocyte Catechol-O-methyltransferase (COMT) activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delay preterm delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Change in ratings on cognitive training survey
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in neural activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in performance on neuropsychological tests
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Time to Plasma Glucose Recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lung Function (Forced Vital Capacity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: HPV DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevention score (point score of cardiovascular risk factors)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean 4-point SMBG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in the human immune system
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Worsening of performance status
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Existence of Tibial Tuberosity Torsion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Pathognomonic sign(s) in the cervix
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic profile (AUC0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of congenital disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Duration of Hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Tissue damage change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain response to immunization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to correct block execution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of drop of intraocular pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Primary Cancers Identified
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Geometric Mean Titer (GMT) of Hemagglutination Inhibition Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: maximum tolerable dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of serum sodium bicarbonate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: VAS of musculo-scrawny pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Changes in general health
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 4 metre gait speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of composite restorations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interbody Radiographic Fusion Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to First Event
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of successful sentinel node biopsies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Complete recovery of urinary continence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: WHODAS Change
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Rumination Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Anhedonia Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion with treatment success in FSS score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Proportion of subjects with a viral load <50 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change from preoperative muscle mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Toxicity of Ho-166 poly lactic microspheres
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Pompe disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage change in mean triglyceride level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Insulin Resistance Index (HOMA-R)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Humoral immunity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Toxicities rate
Endpoint domain: Adverse events/effects
Primary endpoint: Safety and Tolerability-incidence of treatment emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Normalization of Hb-level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Safety and tolerability of ALD403
Endpoint domain: Adverse events/effects
Primary endpoint: fluctuation of heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: fluctuation of blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: fluctuation of arterial partial pressure of carbon dioxide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Hemostasis of vessel staple line
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Cricothyroid membrane position change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of digestive germ peritonitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of Treatment Emergent Clinical Laboratory Test Abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Treatment Emergent Abnormalities in Physical Examination Findings
Endpoint domain: Adverse events/effects
Primary endpoint: Eradication of H Pylori Infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Effects on immune system
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Successful retention of crowns
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score on the positive psychotic dimension of the CAARMS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: In-segment late luminal loss at 8 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Nausea measured by Visual Analogue Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum voluntary contraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: dimensional changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients achieving ASAS20 improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nasal congestion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Rhinorrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Postnasal drip
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Plasma concentrations of glutamine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Owstery disability index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Cumulative area under the concentration-time curve (AUC0-336h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Validity and feasibility of online patient self-assessment system
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Screw resorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Psychotic Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency/amount of substance use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight (lbs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Subjects With Persisting Serum Bactericidal Antibodies Titers ≥4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Plasma Concentration of JNJ-42165279
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Tinnitus Handicap Inventory (THI) scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Performance on Brazelton Neonatal Behavioral Assessment Scale (BNBAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative incidence of new cardiological events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occurrence of new medical pathologies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health status under gluten-containing diet
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in per capita food expenditures
Endpoint domain: Resource use
Endpoint subdomain: Other resource use